| Biomarker ID | 585 |
| PMID | 21266523 |
| Year | 2011 |
| Biomarker | SLCO2B1 (SNP rs12422149) |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Increased risk in GA or AA type allele |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.99; (95% CI: 1.11–3.55) |
| Effect on Pathways | Pathways Include(SLCO1B1):- Recycling of bile acids and salts,Transport of organic anions,Transport of vitamins, nucleosides, and related molecules,Bile acid and bile salt metabolism,Codeine and morphine metabolism,Transport of vitamins, nucleosides, and related molecules,SLC-mediated transmembrane transport |
| Experiment | Prostate Cancer Specific Mortality No No mortality |
| Type of Biomarker | Prognostic |
| Cohort | Out of the 1039 patients, 115 men died of prostate cancer. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | NA |
| Clinical | No |
| Remarks | Only caucasian patients were included in the analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SLCO2B1 |